Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kim, Yun Sook ^a   Do Hwan, Jin ^b   Bae, Sumi ^b   Bae, Dong Han ^a   Ahn Shick, Woong ^b  

^a Soonchunhyang University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C1S; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; DOPACHROME TAUTOMERASE; FORKHEAD BOX PROTEIN P1; I KAPPA B KINASE ALPHA; INTERFERON ALPHA INDUCIBLE PROTEIN 27; INTERFERON ALPHA INDUCIBLE PROTEIN 6; LAMININ; LAMININ BETA 2; LECTIN GALACTOSE BINDING SOLUBLE 3 PROTEIN; MEMBRANE PROTEIN; MURINE RETROVIRUS INTEGRATION SITE 1 HOMOLOG; MYOCYTE ENHANCER FACTOR 2C; NUCLEAR DISTRIBUTION GENE C HOMOLOG PSEUDOGENE 2 PROTEIN; NUCLEAR ENRICHED ABUNDANT TRANSCRIPT 1; NUCLEIC ACID BINDING PROTEIN; RIBONUCLEASE; RIBONUCLEASE K; RNA BINDING MOTIF PROTEIN 5; SINGLE STRANDED DNA BINDING PROTEIN 1; TENASCIN; TENASCIN XB; TRANSCRIPTION ELONGATION FACTOR A LIKE 2; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN 185A; TRK FUSED GENE PROTEIN; UNCLASSIFIED DRUG; X RAY REPAIR COMPLEMENTING DEFECTIVE REPAIR IN CHINESE HAMSTER CELL 6; PRIMER DNA;

ANALYTIC METHOD; ANNEALING CONTROL PRIMER SYSTEM; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; ADULT; AGED; CLUSTER ANALYSIS; CYSTADENOCARCINOMA; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL;

ADULT; AGED; CLUSTER ANALYSIS; CYSTADENOCARCINOMA, SEROUS; DNA PRIMERS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77958043026     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-576     Document Type: Article

References (35)

1. Chang XH, Zhang L, Yang R, Feng J, Cheng YX, Cheng HY, YE X, Fu TY, Cui H. Screening for genes associated with ovarian cancer prognosis. Chin Med J 2009, 122(10):1167-1172.
2. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005, 65:10602-10612. 10.1158/0008-5472.CAN-05-2240, 16288054.
3. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001, 98:1176-1181. 10.1073/pnas.98.3.1176, 11158614.
4. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002, 62:4722-4729.
5. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005, 96:684-694. 10.1016/j.ygyno.2004.11.039, 15721412.
6. Klebanov L, Yakovlev A. How high is the level of technical noise in microarray data?. Biol Direct 2007, 2:9. 10.1186/1745-6150-2-9, 1855048, 17428341.
7. Wan JS, Sharp SJ, Poirier GM, Wagaman PC, Chambers J, Pyati J, Hom YL, Galindo JE, Huvar A, Peterson PA, Jackson MR, Erlander MG. Cloning differentially expressed mRNAs. Nat Biotechnol 1996, 14:1685-1691. 10.1038/nbt1296-1685, 9634852.
8. Debouck C. Differential display or differential dismay?. Curr Opin Immunol 1995, 6:597-599.
9. Liang P, Pardee AB. Recent advances in differential display. Curr Opin Immunol 1995, 7:274-280. 10.1016/0952-7915(95)80015-8, 7546389.
10. Kim YJ, Kwak CI, Gu YY, Hwang IT, Chun JY. Annealing control primer system for identification of differentially expressed genes on agarose gels. Biotechniques 2004, 36(3):424-434.
11. Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer 2006, 118(5):1325-1329. 10.1002/ijc.21486, 16161048.
12. He X, Ota T, Liu P, Su C, Chien J, Shridhar V. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010, 70(8):3109-3118. 10.1158/0008-5472.CAN-09-3557, 20388781.
13. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. All trans retinoic acid increases nitric oxide synthesis by endothelial cells. Circ Res 2002, 90:764-769. 10.1161/01.RES.0000014450.40853.2B, 11964368.
14. Onozato ML, Tojo A, Leiper J, Fujita T, Palm F, Wilcox CS. Expression of DDAH and PRMT isoforms in the diabetic rat kidney; effects of angiotensin II receptor blocker. Dibetes 2008, 57(1):172-180.
15. Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, Hsieh CY, Chen CA. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 2009, 100(7):1144-1153. 10.1038/sj.bjc.6604964, 2669998, 19293794.
16. Hu H, Wang B, Borde M, Nardone J, Maika S, Allred L, Tucker PW, Rao A. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol 2006, 7(8):819-826. 10.1038/ni1358, 16819554.
17. Shi C, Zhang X, Chen Z, Sulaiman K, Feinberg MW, Ballantyne CM, Jain MK, Simon DI. Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. J Clin Invest 2004, 114(3):408-418. 484980, 15286807.
18. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004, 64(17):5963-5972. 10.1158/0008-5472.CAN-04-0020, 15342375.
19. Oliver RI, van Burden M, van't Veer LJ. The role of gene expression profiling in the clinical management of ovarian cancer. Eur J of Cancer 2006, 42:2930-2938.
20. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005, 11:3686-3696. 10.1158/1078-0432.CCR-04-2398, 15897565.
21. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006, 118:1963-1971. 10.1002/ijc.21599, 16287073.
22. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007, 25:517-525. 10.1200/JCO.2006.06.3743, 17290060.
23. Farley J, Ozbun L, Birrer M. Genomic analysis of epithelial ovarian cancer. Cell Res 2008, 18:538-548. 10.1038/cr.2008.52, 18427574.
24. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 2003, 9:4811-4818.
25. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001, 98:1176-1181. 10.1073/pnas.98.3.1176, 14728, 11158614.
26. Lévy P, Ripoche H, Laurendeau I, Lazar V, Ortonne N, Parfait B, Leroy K, Wechsler J, Salmon I, Wolkenstein P, Dessen P, Vidaud M, Vidaud D, Bièche I. Microarray-based identification of Tenascin C and Tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007, 13(2):398-407. 10.1158/1078-0432.CCR-06-0182, 17202312.
27. Chan CC, Menges M, Orzechowski HD, Orendain N, Pistorius G, Feifel G, Zeitz M, Stallmach A. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis 2001, 16:133-140. 10.1007/s003840100287, 11459286.
28. Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler HG, MacLeod RA. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. Leukemia 2008, 22(3):600-7. 10.1038/sj.leu.2405067, 18079734.
29. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 2007, 11(7):955-965. 10.1517/14728222.11.7.955, 17614763.
30. Balasubramanian K, Vasudevamurthy R, Venkateshaiah SU, Thomas A, Vishweshwara A, Dharmesh SM. Galectin-3 in urine of cancer patients: stage and tissue specificity. J Cancer Res Clin Oncol 2009, 135:355-363. 10.1007/s00432-008-0481-4, 18836743.
31. van den Brule FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 1994, 30:1096-1099.
32. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000, 6:1389-1393.
33. Peclet C, de Lamirande G, Daoust R. Sensitivity to RNase treatment of ribosomes and rRNA from normal rat liver and Novikoff hepatoma. Br J cancer 1982, 45:140-143. 2010970, 7059457.
34. Doran G, Allen-Mersh TG, Reynolds KW. Ribonuclease as a tumor marker for pancreatic cancer carcinoma. J Clin Pathol 1980, 33:1212-1213. 10.1136/jcp.33.12.1212, 1146378, 7451669.
35. Naskalski JW, Celinski A. Determination of actual activities of acid and alkaline ribonuclease in human serum and urine. Mater med Pol 1991, 23:107-110.